{"id":"W2964967733","doi":"10.1182/blood.v130.suppl_1.1622.1622","title":"Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; London Health Sciences Centre; CancerCare Manitoba; University Health Network; Ottawa Hospital; University of Alberta Hospital; Alberta Hospital Edmonton; McGill University Health Centre; Hôpital de l'Enfant-Jésus; Juravinski Hospital; Hôpital Maisonneuve-Rosemont; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; BC Cancer Agency","funders":"","keywords":"Discontinuation; Medicine; Dasatinib; Internal medicine; Interim analysis; Imatinib mesylate; Tyrosine-kinase inhibitor; Imatinib; Oncology; Gastroenterology; Clinical trial; Cancer; Myeloid leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002494493,0.0007845924,0.001156542,0.0002138851,0.0007238318,0.0008952544,0.00088907,0.001005134,0.009273041],"category_scores_gemma":[0.002136337,0.0001793056,0.0011462,0.000426032,0.0005103547,0.0004247087,0.0003189648,0.001683529,0.0007857947],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004688867,"about_ca_system_score_gemma":0.01532935,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1031062,"about_ca_topic_score_gemma":0.3278299,"domain_scores_codex":[0.998913,0.0002783215,0.00003879285,0.0001219476,0.000312652,0.0003351712],"domain_scores_gemma":[0.9984325,0.000235094,0.0002876984,0.00009224412,0.0002406395,0.0007118129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7339603,0.004661354,0.02173009,0.001501366,0.003331714,0.0003995609,0.0001807176,0.002992492,0.00496055,0.001540605,0.1003811,0.1243602],"study_design_scores_gemma":[0.6060473,0.09334129,0.2022995,0.0004845398,0.00596863,0.0006911386,0.0001661383,0.003364674,0.004116482,0.002096636,0.08126535,0.0001583257],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7891105,0.01442145,0.003236176,0.01017089,0.001093478,0.01162857,0.09685077,0.0004046451,0.07308363],"genre_scores_gemma":[0.9366373,0.002323809,0.002205325,0.003457726,0.0002498919,0.003457885,0.0375789,0.00004931778,0.01403981],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1031062,"threshold_uncertainty_score":0.205012,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04639728352886525,"score_gpt":0.3133246904818379,"score_spread":0.2669274069529727,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}